Anaplastic Astrocytoma, Glioblastoma Multiforme, Tumor Angiogenesis
Conditions
Keywords
Glioma, DCE-MRI, Angiogenesis, Cancer stem cells, Tumor vasculature
Brief summary
The purpose of the current trial is to explore whether the standard treatment with radiotherapy and temozolomide affect the tumor vasculature in patients with high-grade astrocytomas. If vascular effects are identified, future clinical trials can be proposed wherein anti-angiogenic agents are added to increase patient survival.
Detailed description
Today's standard treatment with radiotherapy and temozolomide yields a life expectancy of 1.5-3 years in patients with high-grade astrocytomas. Thus, there is a need for further therapeutic improvements in this patient population. The purpose of the current trial is to explore whether radiotherapy and temozolomide affect the tumor vasculature in patients with high-grade astrocytomas. If vascular effects are identified, future clinical trials can be proposed wherein anti-angiogenic agents are added to increase patient survival. Additionally, stem cells within malignant brain tumors is an important new area of research in this patient population, and investigations herein could contribute to identify new predictive markers and therapeutic targets. Primary objective: To assess the vascular perfusion and permeability characteristics of high-grade astrocytomas (anaplastic astrocytoma and glioblastoma multiforme) using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in patients receiving radiotherapy and temozolomide. Furthermore to assess whether therapy-induced changes in tumor perfusion is correlated with progression-free survival. Secondary objectives: * Analyze circulating endothelial cells in the blood by flow cytometry to explore whether these cells can be used as an indirect estimate of angiogenesis in high-grade astrocytomas * Analyze tumor specimens from patients that have had their gliomas debulked before commencing therapy * immunostaining of the tumor vasculature to assess microvessel density * immunostaining for tumor stem cells * flow cytometric assessment of dissolved tumor tissue to look for tumor stem cells * Assess progression-free survival of all patients included in the study, in order to correlate the survival data with the above tissue sampling results.
Interventions
DEVICEFunctional MRI (DCE-MRI)
MRI examination with i.v. gadolinium contrast to assess blood perfusion in remaining tumor tissue.
PROCEDUREBlood sample
See protocol.
PROCEDURETumor sample
See protocol.
Sponsors
University of Bergen
Haukeland University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed primary high-grade astrocytoma, i.e. anaplastic astrocytoma or glioblastoma multiforme. * Have a WHO performance status 0-2 and be able to undergo outpatient treatment. * Age ≥18 years. * No pregnant or lactating patients can be included. * Patients must have radiographically documented measurable disease postoperatively. At least one tumor lesion must be unidimensionally measurable as follows: * Tumor lesion \> 10 mm on conventional MRI scan, T1-weighted series, after intravenous (i.v.) gadolinium chelate contrast. * All diagnostic radiology studies must be performed within 28 days prior to registration. * Absence of conditions making MRI scans impossible; * Cardiac pacemaker * Other ferromagnetic metal implants not authorised for use in MRI such as some types of cerebral aneurysm clips * Serious claustrophobia * Obesity (\> 300 lb., 140 Kg) * Patients who are receiving corticosteroids have to receive stable or decreasing doses for at least 14 days before entering the trial. * No prior chemotherapy for high-grade astrocytoma * Absence of opportunistic infections making temozolomide contraindicated. * Minimum required laboratory data: * Hematology: * Absolute granulocytes \> 1.0 x 10\^9/L * Platelets \> 100 x 10\^9/L * Biochemistry: * Bilirubin \< 1.5 x upper normal limit * INR \< 1.5 * Serum creatinine \<1.5 x upper normal limit * Adequate cognitive function in order to give informed consent. * Absence of any psychological, familial or sociological condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial * Before patient registration/randomization, written informed consent must be given according to national and local regulations.
Exclusion criteria
* Lack of fulfillment of inclusion criteria.
Countries
Norway
Outcome results
None listed